


1/10

FIG. 1

IL22

Compound concentration: concentrations of ruxolitinib, calcipotriol, or a combination of thereof;

Calcip = Calcipotriol; Rux = Ruxolitinib; Combinations = Calcipotriol + Ruxolitinib;


MMP12 = Matrix metalloproteinase 12;

Fold change = increase expression over normal (healthy) unstimulated human skin;

Mean + S.E.M: *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001

2/10

FIG. 2



Compound concentration: concentrations of ruxolitinib, calcipotriol, or a combination of thereof;

Calcip = Calcipotriol; Rux = Ruxolitinib; Combinations = Calcipotriol + Ruxolitinib;


MMP12 = Matrix metalloproteinase 12;

Fold change = increase expression over normal (healthy) unstimulated human skin;

Mean + S.E.M: *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001

3/10

FIG. 3

MMP12

Compound concentration: concentrations of ruxolitinib, calcipotriol, or a combination of thereof;


Calcip = Calcipotriol; Rux = Ruxolitinib; Combinations = Calcipotriol + Ruxolitinib;

MMP12 = Matrix metalloproteinase 12;

Fold change = increase expression over normal (healthy) unstimulated human skin;

Mean + S.E.M: * $P < 0.05$; ** $P < 0.01$; *** $P < 0.001$; **** $P < 0.0001$

FIG. 4



5/10

FIG. 5




FIG. 6B

Th17 Stim	Treatment Group		
Gene	Vitamin D Analog	JAK inhibitor	JAKi + Vit D Combo
CAMP			
CCL17			
CCL22			
DefB4a			
FLG			
IFNg			
IL17A			
IL17F			
IL22			
IL31			
IL4			
MMP12			
S100a12			
TNFSF18			
TSLP			

FIG. 6A

Th1 Stim	Treatment Group		
Gene	Vitamin D Analog	JAK inhibitor	JAKi + Vit D Combo
CAMP			
CCL17			
DefB4a			
FLG			
IFNg			
IL17A			
IL22			
IL31			
IL33			
LOR			
MMP12			
S100a12			
SerpinB4			
TNFSF18			
TSLP			

FIG. 7B

Cxcl10




FIG. 7A

Il22

